Galmed Pharmaceuticals Ltd
GPH
Company Profile
Business description
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
Contact
16 Abba Hillel Road
Ramat Gan5250608
ISRT: +972 36938448
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
Our latest stock pitch.
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Market reacts positively to results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,895.80 | 189.10 | -2.08% |
| CAC 40 | 8,274.64 | 33.40 | 0.41% |
| DAX 40 | 24,041.62 | 339.84 | -1.39% |
| Dow JONES (US) | 47,457.22 | 797.60 | -1.65% |
| FTSE 100 | 9,838.00 | 73.42 | -0.74% |
| HKSE | 27,073.03 | 150.30 | 0.56% |
| NASDAQ | 22,870.36 | 536.10 | -2.29% |
| Nikkei 225 | 51,281.83 | 218.52 | 0.43% |
| NZX 50 Index | 13,514.76 | 156.97 | -1.15% |
| S&P 500 | 6,737.49 | 113.43 | -1.66% |
| S&P/ASX 200 | 8,624.00 | 175.40 | -1.99% |
| SSE Composite Index | 4,029.50 | 29.36 | 0.73% |